Bicara Therapeutics Q3 2025 Earnings Report

Bicara Therapeutics EPS Results

• Actual EPS: -$0.67
• Consensus EPS: -$0.55
• Beat/Miss: Missed by -$0.12
• One Year Ago EPS: N/A

Bicara Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Bicara Therapeutics Announcement Details

• Quarter: Q3 2025
• Date: 11/10/2025
• Time: Before Market Opens
• Conference Call Date: Monday, November 10, 2025
• Conference Call Time: 7:30AM ET

Bicara Therapeutics (NASDAQ:BCAX) is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder. Both programs are supported by preclinical validation and early-stage clinical data demonstrating target engagement and potential improvements in mood and social functioning. Bicara’s pipeline leverages translational biomarkers to guide dose selection and patient stratification in ongoing studies.

Founded in 2020 and headquartered in Cambridge, Massachusetts, Bicara Therapeutics completed its initial public offering on the Nasdaq in 2021. The company’s management team brings together experienced leaders from neuroscience, endocrinology and pharmaceutical development. Bicara also collaborates with academic centers and contract research organizations to accelerate its clinical programs and expand the understanding of neurohormone mechanisms in human disease.

Looking ahead, Bicara plans to advance its lead candidates through proof-of-concept studies while exploring additional neurohormone targets for depression, anxiety and other central nervous system indications. By combining peptide chemistry with intranasal formulations, the company aims to address significant unmet needs in mental health and to establish a new class of therapeutics with improved efficacy and tolerability profiles.